{"release_id":19,"data":{"id":91573,"release_id":19,"source_id":"sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision","kind":"observation","fingerprint":"b9f86ed5691a11a0c2f4c76a45105e541327c5e224bafa4525edf38ef58aa872","title_en":"HSA post-marketing vigilance guidance Version 6","title_zh":"HSA\u4e0a\u5e02\u540e\u8b66\u6212\u6307\u5357\u7b2c 6 \u7248","domain":null,"status":"final","assurance":null,"subtype":null,"lat":null,"lon":null,"date":null,"payload":{"bundle_sha256":"45bf7e4a6e04877a9385caa9d5613e31f964959fced55c1117ce10170e4f73ce","checks":{"translation":"passed"},"data":{"denominator":"Guidance scope; not a marketing-authorisation decision and not a declaration that every adverse event is reportable","geography_id":"sg.geo.country.singapore","id":"sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision","kind":"observation","label":"HSA post-marketing vigilance guidance Version 6","metric_id":"sgmetric.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision","population":"Companies responsible for post-marketing surveillance of therapeutic products and CTGTP in Singapore","published_at":"2026-04-01","record_type":"observation","reference_period":"Version 6 uploaded 1 April 2026","retrieved_at":"2026-09-02","revision":"HSA Guidance Version 6","source_url":"https:\/\/isomer-user-content.by.gov.sg\/409\/a6db49dc-ed7f-4e44-93ad-7fb906e7d2f8\/Guidance%20for%20Industry_Post-marketing%20Vigilance%20Requirements%20for%20Therapeutic%20Products%20and%20CTGTP_V.pdf","status":"final","summary":null,"title":"HSA post-marketing vigilance guidance Version 6","unit":"guidance revision","value":"HSA uploaded Version 6 of the post-marketing vigilance guidance on 1 April 2026, revising scope, contact requirements, serious-adverse-event criteria, identifiable-patient examples, literature reports, lack-of-efficacy reports, clinical safety study reports and eCTD submission references"},"date":null,"domain":null,"evidence_paths":["artefacts\/knowledge-graph.jsonl","artefacts\/knowledge-records.jsonl"],"kind":"observation","links":[{"relation":"geography_id","target_id":"sg.geo.country.singapore"},{"relation":"topics","target_id":"sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026"}],"source_id":"sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision","status":"final","summary_en":"","summary_zh":"","title_en":"HSA post-marketing vigilance guidance Version 6","title_zh":"HSA\u4e0a\u5e02\u540e\u8b66\u6212\u6307\u5357\u7b2c 6 \u7248","translation_work":[{"field":"title_zh","fingerprint":"4213400e116b6542afda3d618c23beb44244865f23a3817ebc4e8ad48deed198","source_en":"HSA post-marketing vigilance guidance Version 6","status":"reused"}]},"search_text":"HSA post-marketing vigilance guidance Version 6\nHSA\u4e0a\u5e02\u540e\u8b66\u6212\u6307\u5357\u7b2c 6 \u7248\n\n\n{\"denominator\":\"Guidance scope; not a marketing-authorisation decision and not a declaration that every adverse event is reportable\",\"geography_id\":\"sg.geo.country.singapore\",\"id\":\"sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision\",\"kind\":\"observation\",\"label\":\"HSA post-marketing vigilance guidance Version 6\",\"metric_id\":\"sgmetric.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision\",\"population\":\"Companies responsible for post-marketing surveillance of therapeutic products and CTGTP in Singapore\",\"published_at\":\"2026-04-01\",\"record_type\":\"observation\",\"reference_period\":\"Version 6 uploaded 1 April 2026\",\"retrieved_at\":\"2026-09-02\",\"revision\":\"HSA Guidance Version 6\",\"source_url\":\"https:\\\/\\\/isomer-user-content.by.gov.sg\\\/409\\\/a6db49dc-ed7f-4e44-93ad-7fb906e7d2f8\\\/Guidance%20for%20Industry_Post-marketing%20Vigilance%20Requirements%20for%20Therapeutic%20Products%20and%20CTGTP_V.pdf\",\"status\":\"final\",\"summary\":null,\"title\":\"HSA post-marketing vigilance guidance Version 6\",\"unit\":\"guidance revision\",\"value\":\"HSA uploaded Version 6 of the post-marketing vigilance guidance on 1 April 2026, revising scope, contact requirements, serious-adverse-event criteria, identifiable-patient examples, literature reports, lack-of-efficacy reports, clinical safety study reports and eCTD submission references\"}\n"},"related":[{"id":80313,"source_id":"sg.geo.country.singapore","kind":"geography","title_en":"Singapore","title_zh":"\u65b0\u52a0\u5761","assurance":null,"subtype":"country"},{"id":92733,"source_id":"sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026","kind":"topic","title_en":"HSA Post-marketing Vigilance Guidance 2026","title_zh":"HSA \u4e0a\u5e02\u540e\u76d1\u6d4b\u6307\u5357 2026 \u5e74","assurance":null,"subtype":null}]}